Italian Multicenter Retrospective Observational Study on Transformed Lymphomas

Non-Hodgkin Lymphoma Transformed Recurrent Clinical Trial

— FLT-Oss-2015  

Official title:

Italian Multicenter Retrospective Observational Study on Transformed Lymphomas

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02927756
• Other study ID #: FLT-Oss-2015
• Status: Recruiting
• Phase: N/A
• First received: September 28, 2016
• Last updated: November 22, 2017
• Start date: November 2017
• Est. completion date: June 2018

Study information

• Verified date: November 2017
• Source: Azienda Ospedaliera Città della Salute e della Scienza di Torino
• Contact: Barbara Botto, MD
• Phone: +390116334553
• Email: bbotto[@]cittadellasalute.to.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Study purpose is to evaluate treatment outcome and survival in patient with aggressive lymphomas transformed from Follicular Lymphoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: June 2018
• Est. primary completion date: May 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed transformed Follicular Lymphoma

• Age > 18 years

• Histological transformation between January 2002 and December 2014

• Availability of data about treatment and outcome

Exclusion Criteria:

• Other lymphoma diagnosis

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin
• Non-Hodgkin Lymphoma Transformed Recurrent

Locations

Country	Name	City	State
Italy	SC Ematologia - AOU Città della Salute e della Scienza di Torino	Torino

Sponsors (1)

Lead Sponsor	Collaborator
Azienda Ospedaliera Città della Salute e della Scienza di Torino

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival	Time from last response to nearest relapse or follow-up	From first response to last follow-up for at least 2 years (up to 15 years)
Primary	Overall Survival	Time to last follow-up or death	Date of last follow-up for at least 2 years (up to 15 years)